Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer.

被引：1
|
作者：
Zurcher, Jean-Philippe
Aedo, Veronica
Stravodimou, Athina
Sarivalasis, Apostolos
Zaman, Khalil
机构：
[1] Univ Hosp CHUV, Dept Oncol, Lausanne, Switzerland
[2] Univ Hosp CHUV, Breast Ctr, Lausanne, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e13052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13052
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC)
    Hoskins, Kent F.
    Richards, Paul
    Wisinski, Kari
    CANCER RESEARCH, 2018, 78 (13)
  • [42] Pharmacokinetic assessment of ribociclib, an oral CDK4/6 inhibitor, and the interaction with endocrine therapy partners in patients with advanced breast cancer
    Ji, Yan
    Samant, Tanay
    Quinlan, Michelle
    Chakraborty, Abhijit
    CANCER RESEARCH, 2020, 80 (04)
  • [43] Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study
    Wu, Yun
    Mo, Hongnan
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    Ma, Fei
    Xu, Binghe
    THORACIC CANCER, 2024, 15 (12) : 965 - 973
  • [44] Efficacy of combined CDK4/6 inhibitor and PARP inhibitor in the treatment of BRCA1 mutant triple negative breast cancer
    Zhu, Xiuzhi
    Chen, Li
    Wang, Zhonghua
    CANCER RESEARCH, 2021, 81 (04)
  • [45] Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer
    Hashimoto, Kazuki
    Shimomura, Akihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (13) : 1506 - +
  • [46] The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
    Saleh, Lubaid
    Ottewell, Penelope D.
    Brown, Janet E.
    Wood, Steve L.
    Brown, Nichola J.
    Wilson, Caroline
    Park, Catherine
    Ali, Simak
    Holen, Ingunn
    CANCERS, 2023, 15 (08)
  • [47] HR-positive, HER2-negative Breast Cancer Prolongation of Survival by the CDK4 & 6 Inhibitor Abemaciclib
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) : 690 - 691
  • [48] Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2-and HER2+advanced breast cancer
    Wang, Jingru
    Dong, Xiaotong
    Ashby, Charles R.
    Chen, Zhe-Sheng
    Zhang, Yunxiang
    DRUGS OF THE FUTURE, 2022, 47 (12) : 867 - 886
  • [49] The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
    Yildirim, Eda Caliskan
    Atag, Elif
    Coban, Ezgi
    Unal, Olcun Umit
    Celebi, Abdussamet
    Keser, Murat
    Uzun, Mehmet
    Keskinkilic, Merve
    Simsek, Eda Tanrikulu
    Sari, Murat
    Yavuzsen, Tugba
    BREAST, 2023, 70 : 56 - 62
  • [50] CDK4/6 inhibitors for HR+HER2− early stage breast cancer — when to escalate treatment?
    Giuseppe Curigliano
    Nature Reviews Clinical Oncology, 2021, 18 : 67 - 68
12345